

Chapter 2

The Biology of IgE: Molecular Mechanism Restraining Potentially Dangerous High Serum IgE Titres In Vivo

Gernot Achatz, Gertrude Achatz-Straussberger, Stefan Feichtner,
Sebastian Koenigsberger, Stefan Lenz, Doris Peckl-Schmid,
Nadja Zaborsky, and Marinus Lamers

Abstract Our knowledge about the regulation of the expression of IgE and its biological function is at best limited. We do, however, know that the production of IgE is tightly regulated which is reflected by the fact that the steady-state serum levels of IgE in mice and humans are 3–4 orders of magnitude lower if compared to IgG1, which is an immunoglobulin isotype expressed in response to the same cytokine milieu. What are the rate-limiting steps responsible for this discrepancy? In the following chapter six molecular mechanisms restraining IgE levels will be discussed in detail. The understanding of these mechanisms, combined with the analysis of the biological function of the IgE molecule during an immune response, is the prerequisite for the establishment of new systemic IgE-targeted therapeutic strategies in the future.

2.1 Introduction

IgE is an evolutionary conserved member of the immunoglobulin (Ig) family. Compared to all other Ig classes, which are present in concentrations of micrograms to milligrams per ml serum, the titre of IgE is very low (nano- to micrograms per ml range) in plasma of normal healthy individuals and of normal laboratory mouse strains. IgE is most prominent in epitheliae and mucosae where it is bound to specific receptors on highly potent effector cells like eosinophilic granulocytes and mast cells. Bound to these cells IgE has a long half-life (weeks to months), while free in plasma the half-life is very short (~6 hours). This suggests that IgE plays a role in local immune defence mechanisms. However, the core function for IgE is still unknown. From an evolutionary point of view, IgE is conserved and can be found in all mammalia, including monotremata [1]. It therefore originated at least 160 million years ago, possibly even more than 300 million years ago [2], from a gene duplication of IgY, in which the anaphylactic and opsonic activities of IgY were separated,

G. Achatz (✉)

Department of Molecular Biology, University of Salzburg, Salzburg, Austria
e-mail: gernot.achatz@sbg.ac.at

giving rise to IgE and IgG, respectively [3]. Apparently, in an evolutionary sense, anaphylactic defence mechanisms are needed but at a potentially high price to the organism. The division of anaphylactic and opsonic activities in separate genes allowed principally a tighter and more specific control of both immune mechanisms. In these days IgE is best known for its strong, unwanted effector functions, in the form of allergic reactions [4]. These can range from annoying, local symptoms, like hay fever, to life-threatening, systemic reactions like anaphylactic shock. This underlines the potential hazard of high systemic IgE titres. Remarkably, over the last four decades the incidence of allergic disease has risen. This represents an intriguing problem from a medical, epidemiological, immunological, genetic and evolutionary view. Unfortunately, it is also a major socio-economic problem. One interpretation of these data is that control mechanisms, which were adequate in the past and honed in evolution, are failing.

In the recent past others and we have described several B-cell-specific control mechanisms that indicate a tight control of the IgE response, in agreement with the arguments mentioned above, and that are different from the opsonic type of response (Fig. 2.1):

1. Reduced IL-4-dependent class switch recombination (CSR) to the ϵ heavy chain (ϵ -HC) locus in comparison to the γ -1 (γ 1)-HC locus [5].
2. Short half-life of free IgE in serum, limiting the risk of a systemic anaphylactic reaction [6].
3. Negative feedback function of CD23, the “low” affinity receptor for IgE, resulting in an in-time and quantity-restricted response [7].
4. Direct impact of the membrane (m)IgE receptor on the quality and quantity of the IgE response in vivo [8, 9].
5. Poor expression of mRNA for the membrane form of both the murine and the human ϵ -HC, but not for the murine γ 1- and the corresponding human γ 4-HC [8, 10], resulting in limited expression of IgE as a membrane-bound, antigen-receptor-type molecule [8, 9, 11].
6. Lower chance to contribute to the long-lived plasma cell pool and thus to humoral immunologic memory [12].

In the present review we want to describe these molecular mechanisms and discuss their biological impact on the IgE level in detail.

2.2 Reduced Class Switch Frequency to the IgE Locus

During an immune response, B lymphocytes can switch the Ig isotype from IgM to IgG, IgE, or IgA. This Ig-CSR is based on a DNA recombination event that results in an exchange of the gene segments coding for the constant region of the Ig heavy chain, while retaining the Ig heavy chain variable region. This process changes the effector functions of the corresponding antibody. Much of our current





Fig. 2.1 Schematic overview of B-cell-specific control mechanisms, tightly regulating IgE expression in vivo (1) class switch recombination: Although class switching to IgE and IgG1 is induced by the same cytokine milieu followed by similar signal transduction pathways, a 6-fold reduced switching frequency to IgE is observed. (2) Serum half-life: IgE was reported to degrade between 5 and 12 hours, thus displaying the shortest half-life of all immunoglobulin isotypes. (3) Negative feedback regulation by CD23: CD23-knockout mice show a 6-fold increase in serum IgE level. (4) The IgE antigen receptor: Regulation of quantity and quality of the IgE response directly correlates with the surface expression of mIgE. (5) Alternative polyadenylation: In contrast to all other isotypes, the mIgE-RNA gets polyadenylated by three cryptic poly(A) sites. (6) Plasmablast migration: IgE plasmablasts have an intrinsic lower chance to contribute to humoral memory than IgG1 plasmablasts

understanding of the molecular mechanisms of CSR is based on the analysis of in vitro switched B cells where murine and human naïve B cells can be activated by bacterial lipopolysaccharides (LPS), anti-CD40, or CD40L to undergo CSR. Cytokine signals can direct CSR to distinct classes, e.g. interleukin-4 (IL-4) will target murine IgG1 and IgE, and human IgG4 and IgE, respectively. Class switch to IgE is a very rare process [5], which is tightly regulated and can thus be considered as a further means to keep serum IgE low.

CSR (Fig. 2.2) requires transcription of the S regions, which are located upstream of each isotype constant exon and which subsequently become a substrate for the activation-induced deaminase (AID). AID was first discovered by Muramatsu et al. [13] and soon turned out to be the central enzyme in CSR and hypermutation [14]. AID belongs to the RNA editing deaminase family. It could be shown that AID actually acts on DNA of Ig VDJ and S regions rather than on RNA, thereby deaminating

A



B




Fig. 2.2 The human immunoglobulin locus exhibits an upstream VDJ arrangement followed by several constant regions of different isotypes (**A**). Each isotype (except IgD) consists of a switch region, which has an upstream promoter/I exon region and downstream constant exons for the secreted Ig molecule followed by a poly(A) site for secreted antibody followed by exons M1 and M2 coding for transmembrane and cytoplasmic domains of the respective isotype and a poly(A) site for the membrane version. Also indicated are the promoters of the V, D and I exons and the internal enhancer elements as well as the 3' enhancer. Identified transcription factor sites for the Iε promoter are indicated. (**B**) Upon transcription of the S region, RNA and DNA form a stable R-loop and AID gets access to the S regions and deaminates them causing U/G lesions. These lesions are causing DNA breaks, which ultimately lead to DNA recombination and excision of the intervening DNA as a switch circle

C to U [15]. The generated uracils are subjected to general repair mechanisms, which cause single- and double-stranded DNA breaks [16]. Joining of these ends, presumably by non-homologous end joining mechanisms, ultimately leads to CSR and the excision of the intervening DNA in a switch circle [17]. The central role for AID in CSR and hypermutation was not only shown in AID knockout mice [14] but also in patients who harbour defective AID gene expression or non-functional AID mutants [18]. Further elements are thought to contribute to the Ig isotype-specific targeting of CSR, such as the exact composition of the S region—including stem loop structures, chromatin and DNA modifications, promoter regions and germline transcription (GLT) levels (*cis*-acting elements) – as well as *trans*-acting factors that target the CSR machinery to distinct S regions.

Evidence for the necessity of GLT preceding CSR has come from studies in which deletion of promoter elements that abolished GLT also impaired CSR [19]. Vice versa, enforced transcription of S regions by constitutive or inducible promoter elements leads to induced CSR. This could be shown in knock-in experiments [20] as well as in artificial switch substrates introduced into B-cell lines and even in non-B cells that ectopically express transgenic AID [21]. In any S region, GLT initiates

from a promoter upstream of the germline CSR region (S region). The GLTs comprise a small 5' exon—termed I exon, which is located upstream of the respective S region—spliced to the normal constant heavy chain exons with the intervening S region spliced out from the primary transcript [22]. To exploit GLT as a regulatory mechanism in isotype specificity of CSR, each germline promoter consists of a unique set of transcription factor (TF)-binding sites. In case of the ϵ germline promoter, it could be shown that treatment of primary B cells with the mitogen LPS and IL-4 is sufficient to trigger GLT from IgE [23].

Mitogenic signals like LPS or stimulation of CD40 [24] or signals transmitted by BAFF/April interacting with BAFFR/TACI/BCMA on B cells [25] lead to activation of NF- κ B, which binds to the ϵ promoter together with the TF Stat6 that becomes activated upon IL-4/IL-13 signalling [26]. As shown in Fig. 2.2, several other TFs were identified, which can bind to the ϵ GL promoter like B-cell-specific activation protein (BSAP or Pax5) [27], c-Rel [28], C/EBP and AP1. AP1 only transactivates ϵ GLT from the mouse, but not from the human promoters [29]. TFs that repress transcription from the ϵ promoter are B-cell lymphoma 6 (Bcl-6) and Id2. Bcl-6 was shown to repress IL-4-induced CSR by competing for Stat6-binding sites within the ϵ and γ 1 promoters [30] and Id2 binds to E2A TFs, thereby inhibiting their binding to ϵ promoter elements [31]. Possibly, TFs of the E2A group (E12 and E47) might also play a role in targeting AID to distinct promoter elements of the Ig locus [32] where AID might interact with the transcriptional complex to deaminate S regions [33]. In mouse cell lines, also the TF Ikaros was shown to dampen IgE and IgG GLT by binding to the germline promoter [34]. Schaffer et al. [35] showed that the homeodomain proteins HoxC4 and Oct-1 could bind to I γ and I ϵ promoters to decrease levels of GLT and thus diminish CSR to IgG and IgE [35, 36]. There is also evidence for the 3' enhancer of the Ig locus to selectively interact with promoter regions of the GLTs, in particular with the GL ϵ and γ 2b promoters, which might help to target the recombination machinery to the distinct switch regions [37–39]. However, GLT without splicing of the primary transcript is not sufficient to target switch recombination as deletion of the splice donor site of the I γ 1 exon impaired CSR to IgG1. This shows that CSR also requires processing of the GLTs [40]. Stimulation of B cells with mitogenic signals and IL-4 not only induces GLT from the IgE—but also from IgG1—promoter, which exhibits similar TF-binding sites in its promoter region [41].

The observation that in single B cells more than one isotype-S regions are transcribed [42], together with the fact that AID-mediated DNA deamination is primarily restricted to the Ig locus and is not coupled to all genes that are transcribed in the B cell [22], implies that there have to be further levels of isotype-specific CSR regulation. Initially, it was proposed that due to the high GC contents, S regions are forming stable RNA–DNA hybrids (R-loops) upon transcription, in which the non-template strand remains single stranded and thus serves as a substrate for AID-mediated deamination [43]. However, AT-rich S regions, which are not prone to stable R-loop formation, are also effectively targeted by the CSR machinery, which implies the existence of R-loop-independent AID-recruiting mechanisms [44]. Larson et al. [45] propose that the tertiary G4 DNA structure of transcribed S regions allows specific attraction of repair proteins to S regions, thereby promoting

DNA synapsis and recombination. In addition, histone modifications such as phosphorylation, acetylation and methylation were found to occur in S regions accessible for CSR [33, 46, 47], which were not necessarily coupled to changes in the level of GLT [48]. Additionally, S region length was shown to affect the efficiency of CSR [49]. From these data, it is tempting to speculate that slight differences in S region length, composition and tertiary structures might generate isotype-specific protein-binding sites responsible for isotype-specific targeting of AID to individual S regions. In addition, the C-terminal domain of AID was found to be important for CSR but not for hypermutation, which leads to the assumption that CSR-specific factors might interact with the C-terminal domain of AID to either target AID to specific S regions or to mediate specific DNA synapsis and recombination [50]. Currently, the only published interaction partner for AID is the DNA-binding protein RPA (replication protein A) [51], which binds to AID upon phosphorylation by protein kinase A [52]. Binding of RPA to AID *in vitro* enhances the ability of AID to deaminate cytidines within transcribed double-stranded DNA and probably targets AID to the S region DNA. Further factors that are important in regulating CSR by yet obscure mechanisms, which do not exclude physical interaction with AID/CSR machinery, are the TF Bach2 [53], E47 [32] and Swap70, the latter could be shown to have a positive effect specifically on the IgE response in mice [54].

The puzzling phenotype of patients with Job's or hyper IgE syndrome [55–57] (chronic eczematous dermatitis, recurrent skin and sinopulmonary tract infections, mucocutaneous candidiasis, coarse facies and a remarkably elevated serum IgE level) now seems to be solved and sheds additional light on the complexity of IgE immune response. Job's syndrome is caused by mutations in the DNA-binding domain or the SH2 domain of the TF Stat3 [58, 59]. Whereas the infectious traits of Job's syndrome can be explained by a deficiency in Th17-cell development [60, 61], which severely impairs immune responses to certain bacteria and fungi, the extremely high IgE levels are more diversely discussed. Stat3 is involved in many signalling pathways [62] and the most important TF in IL-21 signalling. In the mouse IL-21 or IL-21R deficiency has been correlated with low levels of serum IgG1 and high levels of IgE [63]. This may be due to an inhibition of CSR to IgE, because IL-21 induces ID2 expression [64]. Stat3, however, also transduces signals for the IL-6 family and the IL-10 family of cytokines and can induce several effector cells, like T and NK cells to produce IFN- γ [62]. All these factors can by themselves influence CSR to the IgE locus and influence the amount of IgE produced [62]. The influence of many ILs and cytokines on the level of expression of IgE clearly incorporates IgE in ongoing immune responses, yet without a clear hint to its core function.

2.3 Serum IgE Has the Shortest Half-Life of All Serum Immunoglobulins

The half-lives of several sets of murine monoclonal antibodies (mAbs) expressing the same V region in combination with all isotypes of serum Igs were determined by Vieira et al. [6] (Table 2.1). IgE was reported to degrade between 5 and 12 hours

Table 2.1 Serum half-lives of immunoglobulins in rodents and humans

Immunoglobulin isotype	Serum half-life ($t_{1/2}$)		
	Mouse ^a	Rat	Human ^c
IgM	2 days	1 days ^e	5–10 days
IgG1	6–8 days	2 days ^e , 9–10 days ^f	21–24 days
IgG2	—	—	21–24 days
IgG2a	6–9 days	4–5 days ^e , 9–10 days ^f	—
IgG2b	4–6 days	2–3 days ^f	—
IgG2c	—	4 days ^f	—
IgG3	6–8 days	—	7–8 days
IgG4	—	—	21–24 days
IgA	17–22 hours	27 hours ^e	—
IgA1	—	—	5.9 days
IgA2	—	—	4.5 days
IgE	12 hours ^a , 5–8 hours ^b	13.1 ± 5.7 hours ^d	1–5 days

^aVieira et al. [6], ^bHaba et al. [65], ^cLeffell et al. [168], ^dHanashiro et al. [67], ^ePeppard and Orlans [169] and ^fMedesan et al. [170].

[6, 65], thus displaying the shortest half-life of all Ig isotypes. Additionally, alterations in the half-life of IgE were reported in dependency of the site of application. Hirano et al. [66] published that intravenously injected murine anti-DNP-IgE persisted for 12 hours whereas intradermally injected IgE was stable for at least 6 days. Similar half-lives for rat IgE (13.1 ± 5.7 hours) were published by Hanashiro et al. [67].

Waldmann et al. [68] hypothesized that an increased catabolic rate of IgE is dependent on the existence of intravascular and/or extravascular compartments. Human IgE is metabolized mainly in the extravascular compartment and the catabolism of IgE is related to the interaction of IgE with Fcε-receptor (FcεR)-bearing cells. In contrast, it has also been speculated that the vascular endothelium represents a site of catabolism of IgE. Interestingly, an FcRn (Brambell receptor [69]) knockout reduced the serum half-life of IgG1 in mice from 9 to 1.4 days. Thereby, IgG1 in FcRn-knockout mice has roughly the same half-life as all other Ig isotypes in mice [70]. Moreover, Lu et al. [71] generated transgenic mice that overexpressed the bovine FcRn (bFcRn) in their lactating mammary glands. Significantly increased IgG levels were observed in the sera and milk from transgenic animals, suggesting that the overexpressed bFcRn binds and protects endogenous mouse IgG and thus extends its life span. These results indicate that the main reason for the difference in the half-life time between IgG and IgE is explained by the stabilizing interaction between IgG and FcRn. Additionally, the MHC class I-related protein FcRn, originally identified by Simister and colleagues [72, 73] plays a critical role in IgG homeostasis by protecting IgG from normal protein catabolism, which results in a substantial increase in the half-life of IgG.

Similarly, the interaction between IgE and FcεRI stabilizes both partners, increasing the half-life of cell-bound IgE to months. The decreased sensitivity to decay

is accompanied by a conformational change in the three-dimensional structure of IgE: binding to the Fc ϵ RI causes the protein to open up from a bent shape into a more stretched shape, leaving the antigen-binding sites intact [4]. The majority of IgE in the body is probably bound to Fc ϵ RI on basophils and mast cells, whereas IgG is primarily found in the free, circulating form. Nevertheless, the short half-life of unbound (free) IgE in the blood limits the danger of a systemic anaphylactic reactions.

2.4 CD23 Influences IgE Expression by a Negative Feedback Inhibition

In humans two isoforms, CD23a and CD23b, differing in the first six cytoplasmic amino acids [74, 75] were described. While CD23a is constitutively expressed on B cells and follicular dendritic cells, CD23b, after IL-4 stimulation, is expressed on a variety of hematopoietic cell types like B cells, monocytes, eosinophils and Langerhans cells [75–77]. For a long time only one CD23 isoform was known in mouse, corresponding to human CD23a, but recent studies also described the existence of the CD23b isoform. However, CD23 expression in mouse is restricted to B cells (CD23a) and follicular dendritic cells (CD23a and CD23b) [78–80].

Unlike other Fc receptors, CD23 does not belong to the Ig superfamily of proteins, but is a 45 kDa type II transmembrane glycoprotein comprising a C-terminal lectin domain, followed by a stalk region, a transmembrane domain and a short cytoplasmic tail [81, 82]. The lectin domain binds IgE via the C ϵ 3 domain in a calcium-dependent way [83, 84]. CD23 is expressed on the cell surface as trimers [82, 85]. Oligomerization mediates high-affinity binding to IgE, where two lectin heads bind to one IgE molecule [82]. CD23 binds IgE with both a medium affinity ($4\text{--}10 \times 10^7 \text{ M}^{-1}$) and a low affinity ($4\text{--}10 \times 10^6 \text{ M}^{-1}$) [86]. Besides this membrane-bound form (mCD23), CD23 also exists as soluble fragments of different sizes (sCD23) when cleaved by an autocatalytic mechanism mediated by the metalloprotease ADAM10 [87, 88]. With the exception of one soluble fragment, all of them contain the IgE-binding lectin domain and can bind IgE with low affinity in the range from 10^5 to 10^6 M^{-1} [89].

CD23 is a pluripotent molecule; its biological functions include cell activation and proliferation, cell adhesion, IgE-dependent antigen transport, processing and presentation as well as regulation of IgE synthesis and expression. However, the most striking phenomenon is CD23's ambiguous function on IgE regulation, both in activation and/or inhibition of IgE production. Several studies with CD23-deficient and CD23-overexpressing mice clearly demonstrated CD23's role as a negative feedback regulator of IgE production [90–95]. Yu et al. [7] showed that disruption of the CD23 gene led to increased specific IgE levels after immunization with TD antigens. While IgG1 levels were twice as high after immunization with 2,4-dinitrophenyl-ovalbumin (DNP-OVA), specific IgE levels were 6–12 times higher in these mice. In contrast, mice overexpressing CD23 produce much lower amounts of IgE, confirming CD23 as a potent regulator of IgE production. Experiments with

New Zealand black mice, which cannot form trimers of CD23 and therefore show impaired high-affinity binding of IgE, also have an exaggerated IgE response [96]. Furthermore, anti-CD23 antibody treatment inhibits specific IgE responses and anti-stalk antibodies enhance IgE production and promote cleavage of mCD23 [97–102]. This increase can be attributed to the prevention of cooperative association of the IgE-binding lectin domains, therefore interfering with oligomerization and high-affinity binding of CD23 [85, 98]. Kilmon et al. [98] demonstrated that RAS1, an anti-stalk antibody, not only prevents oligomerization of CD23 but also inhibits the release of mCD23 [98]. Mice treated with RAS1 and immunized with KLH-DNP/Alum with pertussis toxin also expressed higher levels of IgE, comparable to CD23^{-/-} mice. mAB 19G5 also inhibited high-affinity IgE binding and led to increased IgE levels, but unlike RAS1, 19G5 favoured cleavage of mCD23, leading to elevated sCD23 levels (100–150-fold) [85, 103]. Kinetics of the IgE response were comparable with a primary immune response. Thus, here the elevated serum levels were simply the result of cytophilic release of CD23-bound IgE. Ford et al. [103] also showed that IgE levels are increased even in the absence of Ag-alum, indicating that CD23's negative regulation of IgE can be abrogated by destabilizing CD23. These results clearly revealed CD23's ambiguous function on IgE regulation: while stabilized mCD23 negatively regulates IgE production, destabilization of mCD23 leads to an increase of IgE.

Summarizing, in the early phase, IL-4 activates expression of both IgE and CD23, whereas later on, when IgE levels have reached a certain threshold, binding of IgE to CD23 stabilizes and prevents degradation of CD23. This inhibits ongoing IgE synthesis and dampens the immune reaction. However, CD23 seems to play only a role in regulating moderate amounts of IgE: first, helminth-infected wild-type and CD23^{-/-} mice showed the same IgE response [7] and second, destabilization of mCD23 via 19G5 treatment did not lead to an increase of IgE in helminth-infected mice [103].

Many studies have been performed to address the mechanisms behind CD23's regulatory function. Aubry et al. [104] showed that sCD23 enhances IgE synthesis by binding to CD21 on peripheral blood B cells. Christie et al. [105] prevented autocatalytic cleavage of mCD23 and measured reduced IgE levels. In contrast, Texido et al. [92] showed that transgenic mice for sCD23 exhibited no phenotype, indicating that it is the membrane-bound form of CD23 that regulates IgE production. Ford et al. [103] investigated the role of CD21, a natural ligand for CD23. By using CD21-deficient mice it could be demonstrated that the 19G5-induced IgE response is independent of CD21 signalling, suggesting that increased IgE levels can be attributed to the loss of mCD23 and the release of CD23-bound IgE and not to the accumulation of sCD23 [103]. Recent studies from McCloskey et al. [106] showed that sCD23 both inhibits and stimulates IgE production, depending on the structure of the fragments: while sCD23 monomers inhibit IgE synthesis in human B cells, oligomers stimulate synthesis by co-ligating IgE and CD21 on IgE⁺ B cells.

Summarizing, binding of IgE to mCD23 stabilizes the trimer and prevents its degradation, thus inhibiting the autocatalytic release of sCD23 fragments, which stimulate (in oligomeric form) IgE synthesis. Data from McCloskey et al. [106]

confirmed the competition model between CD23 and CD21 for membrane-bound IgE on the B-cell surface proposed by Hibbert et al. [107]. Co-cross-linkage of mCD23 and mIgE by an IgE/Ag complex results in a decrease of IgE; co-cross-linking of CD21 and mIgE by sCD23 leads to an increase of IgE [107]. Still, the mere absence of CD23, as we have seen, suffices to increase IgE responses.

2.5 The Biological Function of the mIgE Antigen Receptor on IgE Synthesis In Vivo

The B-cell receptor (BCR) is undoubtedly the most important component of a B cell's interface regarding communication with the local environment. Main developmental steps taking place in the bone marrow like signalling through the pre-BCR as well as avoiding autoreactivity by clonal deletion or receptor editing utterly rely on the expression of a functional receptor. In the periphery, the BCR is one of the driving forces establishing antibody responses addressing invading pathogens and it has been shown to be essential for maintaining peripheral B-cell tolerance in the case of B-cell anergy [108]. Regarding mIgE, the relevance of the receptor seems restricted to responding secondary lymphoid organs like the spleen, lymph nodes and Peyer's patches. Here, the decision to switch to mIgE⁺ plasmablasts and finally to IgE-producing antibody-secreting cells (ASCs) is being made in an adequate cognate T-cell-help and cytokine context [109].

mIgE, in contrast to its soluble form, contains three additional structural features encoded by exon M1 and M2, namely the *EMPD* (extracellular membrane-proximal domain) domain, the *transmembrane domain*, which anchors the receptor in the cell membrane and serves as interaction domain for the CD79 α/β sheath to form the BCR [110, 111] and the *cytoplasmic domain*. The EMPD regions of the five isotypes differ in length and amino acid composition. In human IgE two functional forms of ϵ_{EMPD} , namely ϵ_{short} and ϵ_{long} , exist composed of 14 and 66 amino acids, respectively [112–114]. According to a study of Poggianella et al. [115] carried out in the mature murine B cell line A20, the presence of the EMPD region is of critical importance for mobilizing intracellular Ca²⁺, with the EMPD's length apparently being the “sensor” of caspase-independent apoptosis sensitivity. A similar phenomenon of inhibition of proliferation has been reported in murine WEHI-231 cells transfected with the shorter human version of mIgE [116]. This study also showed that the rate of transport by which the two forms are brought to the cell surface as well as the association with CD79 α and the kinetics of protein tyrosine phosphorylation in response to receptor cross-linking differs between the short and the long version. Thus, the form of the EMPD region might have an essential function in shaping the repertoire of mIgE⁺ plasmablasts selected towards the long-lived plasma cell fate.

A step forward in the understanding of the role of mIgs other than mIgM or mIgD was achieved with two mouse lines with mutations in the ϵ -HC gene. In the first, the intracellular domain of IgE was removed except for three amino acids (Lys, Val and Lys) (KVK Δ tail line). The cytoplasmic domain of IgE in these mice is the same as

that of mIgM and mIgD. In the second line both the intracellular and the transmembrane domains of IgE (Δ M1M2 line) are lacking [9]. In Δ M1M2 mice serum IgE is reduced to less than 10% of normal mice, while KVK Δ tail mice show a reduction of 50%, reflecting a serious impairment of the IgE-mediated immune response. Class switch to IgE was not impaired by the targeting event. Upon stimulation of isolated spleen cells of wild-type, Δ M1M2 and KVK Δ tail mice with LPS and IL-4 *in vitro*, concentrations of IgE and IgG1 in the culture supernatants were comparable in wild-type and mutant mice. These results imply that the reduced IgE titres found in both mutant lines are solely a reflection of the loss of biological activities associated with the transmembrane and cytoplasmic domains of IgE. These data clearly show that the transmembrane domain of IgE is indispensable for a T-cell-dependent IgE-mediated immune response and that the cytoplasmic tail not only determines the absolute amount of IgE produced but also the quality of the antibodies. How does this work?

Two hypotheses can be brought forward. The first implies that signals generated via membrane-bound Ig are needed at all times, not only for the maturation process, but also for the expansion of antigen-specific cells. The second hypothesis postulates that antigen presentation to T-helper cells is necessary at all times during an antibody response and that the antigen receptor is the only device for an effective antigen presentation. The hypotheses are not necessarily mutually exclusive. All Ig classes can associate with the Ig- α /Ig- β heterodimer [117], the signal-transducing unit of the BCR. Recent experiments have shown that an intact antigen receptor on B cells is elementary for the survival of B cells [118]. It is not clear from these experiments which function the antigen receptor performs: interactions with external ligands, maintenance of a tonic signal generated by the mere presence of the receptor in the membrane, or capture of antigen. Both the Ig- α /Ig- β sheath and the cytoplasmic tail of mIg [119] have been implied in guiding antigen bound via the receptor to the antigen-processing compartments. Key residues for internalization are present in the tails in the form of an YxxI/M motif. This could be a prerequisite for processes that are highly dependent on T-B cell interactions like somatic mutation and affinity maturation and the generation of memory cells, but also processes like the rescue from apoptosis and the induction of plasma cells. These considerations predict that the results we obtained in the KVK Δ tail and Δ M1M2 lines can be extended to the IgG isotypes and perhaps to IgA. Indeed, Kaisho et al. [120] reached matching conclusions, studying mice carrying similar mutations in the γ 1 gene. The phenotype of the mIgG mutants is, however, more prominent.

Further studies showed that upon receptor ligation, the mere cytoplasmic tails of γ and ϵ but not μ , δ , or α are capable of inhibiting CD22 phosphorylation and SHP-1 recruitment [121, 122]. Due to the fact that none of the cytoplasmic tails of mIgs contain full ITAM/ITIM motifs [123], tail-interacting proteins may influence downstream B-cell signalling cascades. A study of Batista et al. [116] identified two proteins, namely ϵ BAP37 and ϵ BAP41, being exclusively associated with the cytoplasmic tail of mIgE. Those two molecules were shown to be glycosylated and form disulphide-bonded complexes, with each having an extracellular domain. Recently, we described another protein, involved in mIgE-mediated

signalling, HS1-associated protein X-1 (HAX-1). HAX-1 turned out to be associated with the mIgE tail, being indispensable for the internalization of the receptor by linking it to the cytoskeleton via its interaction with HS1 [124].

Additionally, Erazo et al. [125] suggested a model, in which IgE⁺ cells exhibit a plasma cell programme from early onwards, with signs of somatic hypermutation despite their exclusion from GCs, with repression of Bcl6 and upregulation of Blimp-1, a central TF in plasma cell differentiation [126]. They further hypothesized that expression of mIgE requires an intermediate IgG1⁺ cellular phase, leading to high-affinity IgE antibodies without requiring a prolonged IgE⁺ GC phase. In contrast, Kelly et al. [127] claimed that in their system of administering phOx-BSA into the footpad of mice and monitoring the response in brachial lymph nodes, the majority of IgE⁺ cells are localized in GCs. The notion that CSR to IgE is an actively inhibited process, as was revealed in IL-21- and IL-21R-knockout mice, which are characterized by low IgG and high IgE titres [63], does not support a consecutive switch model. In respect to additional partially controversial literature [128, 129] one can speculate that not only the type and the amount of administered antigen, but also the route of administration and the involved cytokines seem to be of critical importance concerning the nature of the response.

2.6 Impaired Splicing and Polyadenylation Restricts the Generation of a Mature mIgE Transcript

Both of the mRNAs for the secreted and the membrane form of IgHCs are generated from the same precursor mRNA by means of alternative splicing and polyadenylation. The third (IgD and IgGs) or fourth (IgM and IgE) constant exon, which is located 5' of the transmembrane and the cytoplasmic exons, is a composite exon: it contains an internal splice donor site which is used when mRNA for membrane-bound Ig is made. It is also followed by an "internal" polyadenylation-addition site that is used when mRNA for secreted Ig is made. A 3' "external" polyadenylation-addition site is found downstream of the membrane exons. With the exception of IgE, the consensus sequence AATAAA is used for the "internal" and the "external" polyadenylation signals. Looking at the mRNA levels of both forms in the course of B-cell development, a shift in the membrane-to-secreted ratio can be observed [130]. While resting B cells produce similar amounts of both mRNA's, the ratio changes in favour of the secreted form in activated B lymphoblasts and in the terminally differentiated B cell, the plasma cell, mRNA for the secreted form is 20–100 times higher abundant than mRNA for the membrane form. This change in the membrane-to-secreted ratio does not seem to be caused by an increase in transcription rate, since the heavy chain enhancer is already completely active in the pre-B-cell stage [131]. This shift is far more likely generated by a selective increase in the processing rate and in the stability of secretory mRNA [132]. It is known for a long time that polyadenylation has a paramount effect on mRNA stability, nuclear export and translation. The process of polyadenylation requires numerous factors responsible for the




Fig. 2.3 Polyadenylation consensus sequences of mouse immunoglobulin isotypes. **(A)** An ideal polyadenylation consensus sequence (AAUAAA) and a perfectly positioned GU-rich region is shown. “CA” marks the site of actual cleavage and subsequent polyadenylation. **(B)** The secretory and membrane poly(A) sites of the immunoglobulin isotypes in mouse are shown. All sites except ϵ membrane poly(A) have a single AAUAAA consensus sequence. The ϵ membrane poly(A) site is made up of three “cryptic”-poly(A) sites. The μ secretory poly(A) site depicts a distinct dual structure, which is not found in the other isotypes. It has an upstream AU-rich region and two suboptimally placed GU-rich motifs, weakening the μ secretory poly(A) site

recognition, cleavage and addition of the poly(A) tail. Two multisubunit complexes, designated cleavage-polyadenylation specificity factor (CPSF) [133–135] and cleavage stimulation factor (CstF) [136], cooperate with each other to define the site of polyadenylation [137, 138]. They recognize the highly conserved AAUAAA hexanucleotide (Fig. 2.3) [137, 139] and a more divergent GU-rich sequence located downstream of the actual cleavage site [140–142]. Two additional factors, cleavage factor I and II (CFI and CFII), are further necessary for the cleavage reaction [135]. For the poly(A) synthesis itself, CPSF and poly(A) polymerase [143–145], together with poly(A)-binding protein II (PAB II), are sufficient, although CstF was recently shown to enhance this reaction [146]. A subunit of the CstF, CstF-64, was shown to be expressed in a stage-specific manner in B cells expressing IgM [141, 147]. It was speculated that in resting B cells, where CstF-64 is less abundant, the poly(A) site for the membrane form of μ (μ_m poly(A) site) is preferred over that of the secreted form (internal or μ_s poly(A) site). The higher amount of CstF in activated plasma cells leads to the better recognition of the “weaker” internal μ_s poly(A) site [147]. A supposed mechanism for this phenomenon is that polyadenylation of the μ_s poly(A) site takes place before transcription over the μ_m poly(A) site can proceed. However, this phenomenon was found to be valid for IgM [148–150] but not for IgG and IgA [151–153]. For IgG2b, not the increasing amount of CstF-64 during B-cell development is important but rather the improved binding and polyadenylation efficiency [154]. Further, Yan et al. [44] postulated a specific activity in B-cell extracts that selectively impairs the formation of a μ_s poly(A) site processing complex, suggesting that the function of this poly(A) site may be regulated by both positively and negatively acting factors. Additionally, the sequence of the intron 5' of the M1 exon can influence the polyadenylation/splicing balance. For IgA a specific sequence in

the $\text{Ca3-M}\alpha 1$ intron is recognized by a 58 kDa protein and leads to a predominant usage of the αs poly(A) site [153, 155]. In this special case, the ratio of αs -to- αm IgA in resting B cells is about 2. Therefore it is possible that *cis*-acting elements unique to each HC gene act upon a common mechanism regulation Ig mRNA processing.

The ϵ -HC gene differs from the Ig genes as to its 3' external ϵm poly(A) site (Fig. 2.3). Here, three kryptic "external" polyadenylation signals (AGTAAA, AAGAAA and ATTAAA) are found, which are in considerable disagreement with the consensus sequence (AATAAA). As we have seen, the ratio of transcripts for the secreted and the membrane form of Ig reflects the usage of either polyadenylation signal. The poor 3' polyadenylation sites in the ϵ gene unfavourably influence the production of mRNA for the membrane form of ϵ [10]. One of the consequences of the restricted polyadenylation of the ϵm transcript is a limited stable pool of ϵm mRNA which further influences the poor expression of the membrane-associated IgE-BCR on switched B cells. Surface expression of the membrane form of IgE is paramount to the survival of IgE switched B cells [9]. Therefore, weak 3' processing of $\text{m}\epsilon$ -mRNA seems to be a way to keep numbers of IgE-positive B cells and thus the titre of secreted IgE in the serum low.

Another interesting feature is that the human ϵ gene *in vitro* generates more than two mRNAs for the secretory and the membrane-associated forms, generated via alternative splicing and polyadenylation. Burrone et al. have found and characterized two functional membranes and two functional secretory isoforms out of six possible isoforms. All four heavy chains seem to assemble into proper Igs, although with different kinetics, and are functionally active as a receptor or as a mediator of a humoral immune response [116, 156, 157].

2.7 IgE Plasmablasts Have an Intrinsic, Lower Chance to Contribute to the Long-Lived Plasma Cell Pool

It is generally accepted that the switch of B cells expressing membrane-bound Igs, which serve as antigen receptors, to antibody-secreting plasmablasts and finally non-dividing, long-lived plasma cells, marks the terminal differentiation of a B cell. Thus, besides memory B cells, antibody-secreting plasma "memory" cells represent the key cell type for the maintenance of humoral immunological memory. Although some populations of long-lived plasma cells persist in the spleen, most of them return to their "place of birth" and invade the bone marrow or inflamed tissues where they survive as resident, immobile cells in survival niches up to several months [158–160]. However, the life span of plasma cells is limited by the immigration of newly formed migratory plasmablasts that compete with old plasma cells for their survival niches. In these niches, resident long-lived plasma cells are resistant to therapies targeting activated and/or proliferating lymphocytes, for example, by radiation [161] or cyclophosphamide [162]. The permanent and antigen-independent secretion of antibodies specific for allergens or autoantigens makes these cells key players in allergic and autoimmune diseases and obviously key targets for possible therapeutic interference.

The migration of plasmablasts to the bone marrow is a critical differentiation step for long-lived plasma cells. Little is known about the migration of ASCs in general and ASCs of IgE in particular. Chemokines and their receptors are crucially involved in the control of lymphocyte trafficking. Hauser et al. [163, 164] showed that migratory cells lose responsiveness to many chemokines, with the exception of chemokine ligand (CXCL) 12 and CXCL9. The corresponding receptors, sensitive for CXCL12 and CXCL9, were identified as chemokine receptor (CXCR) 4 and CXCR3, respectively. It has recently been suggested that the chemokine receptor CXCR4 is required for normal accumulation of plasma cells in the bone marrow [165], as demonstrated by the increased sensitivity of the CXCR4 receptor for its ligand CXCL12, which is mainly expressed in the splenic red pulp, the lymph node medullary cords and the bone marrow.

Muehlinghaus [166] first pointed out the importance of the antigen receptor for migration behaviour of memory B cells. It was shown that CXCR3 is preferentially expressed on a fraction of human memory B cells, in particular on those expressing IgG1. Further, CXCR3⁺ memory B cells upregulate CXCR3 and migrate towards concentration gradients of its ligand only when co-stimulated with interferon γ but not with IL-4.

In order to analyse the migratory behaviour of memory B cells in the dependence of the isotype of the antigen receptor, we constructed “knock-in” mouse strain KN1, where we completely exchanged the membrane ϵ -genomic region downstream of the secretory poly(A) site for the membrane γ 1-region [167]. Thus, in KN1 the IgE immune response develops under the regulation of γ 1-specific cytoplasmic signalling. KN1 not only showed a significant increase in mRNA for the membrane and secreted ϵ -transcripts, but also a 6-fold increase in serum IgE. The continually accumulating serum IgE titre is the result of a selection advantage of chimeric mIgE-expressing B cells in KN1 mice for their immigration to the bone marrow. The γ 1-based signalling in chimeric mIgE-B cells indicates the existence of an isotype-specific, antigen-receptor-dependent developmental programme for B cells to become long-lived plasma cells.

Summarizing, our data strongly support the concept that BCR-mediated signalling continues in the plasmablast stage and has an isotype-specific component: γ 1-like signalling, in contrast to ϵ -like signalling, facilitates migration of plasmablasts towards the chemokine CXCL12, allowing them to settle in plasma cell niches, like in the bone marrow, and (thus) more efficiently induces progression towards the fully matured plasma cell stage. Our observations also lead to the conclusion that during a Th2-mediated immune response, in normal wild-type mice, IgE plasmablasts have an intrinsic lower chance to contribute to the long-lived plasma cell pool and thus to humoral immunologic memory than IgG1 plasmablasts.

2.8 Conclusions

Our knowledge about the regulation of the expression of IgE is at best limited. Unfortunately, a similar statement can be made regarding the function of membrane-bound IgE. We do, however, know that the production of IgE is tightly regulated.

This regulation is evident on the level of DNA (switch) recombination, transcription and RNA processing. It is not inconceivable that also post-translational processes may influence the expression of membrane-bound IgE. The consequences of a possible dysregulation, i.e. uncontrolled IgE secretion, warrant an in-depth study of these processes.

Summarizing, IgE antibodies may have strong effector functions, but this contrasted with the slow IgE response and the limited development of memory responses. Together these observations represent mechanisms to restrain potentially dangerous, but apparently necessary, because present, high serum IgE titres at many different levels in a biological process.

Acknowledgements Experimental work and publication charges were supported by the Austrian Science Foundation (P19017-B13), the Austrian National Bank (OENB grant: 11710) and the Christian Doppler Laboratory for Allergy Diagnosis and Therapy.

References

1. Verneris M, Aveskogh M, Hellman L (2004) Cloning of IgE from the echidna (*Tachyglossus aculeatus*) and a comparative analysis of epsilon chains from all three extant mammalian lineages. *Dev Comp Immunol* 28:61–75
2. Kumar S, Hedges SB (1998) A molecular timescale for vertebrate evolution. *Nature* 392:917–920
3. Warr GW, Magor KE, Higgins DA (1995) IgY: Clues to the origins of modern antibodies. *Immunol Today* 16:392–398
4. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L (2003) The biology of IGE and the basis of allergic disease. *Annu Rev Immunol* 21: 579–628
5. Siebenkotten G, Esser C, Wabl M, Radbruch A (1992) The murine IgG1/IgE class switch program. *Eur J Immunol* 22:1827–1834
6. Vieira P, Rajewsky K (1988) The half-lives of serum immunoglobulins in adult mice. *Eur J Immunol* 18:313–316
7. Yu P, Kosco-Vilbois M, Richards M, Kohler G, Lamers MC (1994) Negative feedback regulation of IgE synthesis by murine CD23. *Nature* 369:753–756
8. Achatz G, Luger E, Geisberger R, Achatz-Straussberger G, Breitenbach M, Lamers M (2001) The IgE antigen receptor: a key regulator for the production of IgE antibodies. *Int Arch Allergy Immunol* 124:31–34
9. Achatz G, Nitschke L, Lamers MC (1997) Effect of transmembrane and cytoplasmic domains of IgE on the IgE response. *Science* 276:409–411
10. Karnowski A, Achatz-Straussberger G, Klockenbusch C, Achatz G, Lamers MC (2006) Inefficient processing of mRNA for the membrane form of IgE is a genetic mechanism to limit recruitment of IgE-secreting cells. *Eur J Immunol* 36:1917–1925
11. Luger E, Lamers M, Achatz-Straussberger G, Geisberger R, Infuhr D, Breitenbach M, Cramer R, Achatz G (2001) Somatic diversity of the immunoglobulin repertoire is controlled in an isotype-specific manner. *Eur J Immunol* 31:2319–2330
12. Achatz-Straußberger G, Königsberger S, Karnowski A, Lamers M, Achatz G (2007). Elevated histamine release in chimeric IgE/IgG1 antigen receptor knock-in mice. *Allergy Clin Immunol Int Hogrefe & Huber Supp* 2:121–123
13. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T (1999) Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. *J Biol Chem* 274: 18470–18476

14. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell* 102:553–563
15. Petersen-Mahrt SK, Harris RS, Neuberger MS (2002) AID mutates *E. coli* suggesting a DNA deamination mechanism for antibody diversification. *Nature* 418:99–103
16. Di Noia J, Neuberger MS (2002) Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. *Nature* 419:43–48
17. Kenter AL (2005) Class switch recombination: an emerging mechanism. *Curr Top Microbiol Immunol* 290:171–199
18. Durandy A, Taubenheim N, Peron S, Fischer A (2007) Pathophysiology of B-cell intrinsic immunoglobulin class switch recombination deficiencies. *Adv Immunol* 94:275–306
19. Linehan LA, Warren WD, Thompson PA, Grusby MJ, Berton MT (1998) STAT6 is required for IL-4-induced germline Ig gene transcription and switch recombination. *J Immunol* 161:302–310
20. Xu L, Gorham B, Li SC, Bottaro A, Alt FW, Rothman P (1993) Replacement of germline epsilon promoter by gene targeting alters control of immunoglobulin heavy chain class switching. *Proc Natl Acad Sci USA* 90:3705–3709
21. Yoshikawa K, Okazaki IM, Eto T, Kinoshita K, Muramatsu M, Nagaoka H, Honjo T (2002) AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. *Science* 296:2033–2036
22. Di Noia JM, Neuberger MS (2007) Molecular mechanisms of antibody somatic hypermutation. *Annu Rev Biochem* 76:1–22
23. Rothman P, Li SC, Gorham B, Glimcher L, Alt F, Boothby M (1991) Identification of a conserved lipopolysaccharide-plus-interleukin-4-responsive element located at the promoter of germ line epsilon transcripts. *Mol Cell Biol* 11:5551–5561
24. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA, Jr., Flavell RA (1996) Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. *Science* 273:1864–1867
25. Claudio E, Brown K, Park S, Wang H, Siebenlist U (2002) BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. *Nat Immunol* 3:958–965
26. de Vries JE, Punnonen J, Cocks BG, de Waal Malefyt R, Aversa G (1993) Regulation of the human IgE response by IL4 and IL13. *Res Immunol* 144:597–601
27. Thienes CP, De Monte L, Monticelli S, Busslinger M, Gould HJ, Vercelli D (1997) The transcription factor B cell-specific activator protein (BSAP) enhances both IL-4- and CD40-mediated activation of the human epsilon germline promoter. *J Immunol* 158:5874–5882
28. Agresti A, Vercelli D (2002) c-Rel is a selective activator of a novel IL-4/CD40 responsive element in the human Ig gamma4 germline promoter. *Mol Immunol* 38:849–859
29. Shen CH, Stavnezer J (2001) Activation of the mouse Ig germline epsilon promoter by IL-4 is dependent on AP-1 transcription factors. *J Immunol* 166:411–423
30. Harris MB, Chang CC, Berton MT, Danial NN, Zhang J, Kuehner D, Ye BH, Kvatyuk M, Pandolfi PP, Cattoretti G, Dalla-Favera R, Rothman PB (1999) Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of epsilon transcription and immunoglobulin E switching. *Mol Cell Biol* 19:7264–7275
31. Sugai M, Gonda H, Kusunoki T, Katakai T, Yokota Y, Shimizu A (2003) Essential role of Id2 in negative regulation of IgE class switching. *Nat Immunol* 4:25–30
32. Schoetz U, Cervelli M, Wang YD, Fiedler P, Buerstedde JM (2006) E2A expression stimulates Ig hypermutation. *J Immunol* 177:395–400
33. Nambu Y, Sugai M, Gonda H, Lee CG, Katakai T, Agata Y, Yokota Y, Shimizu A (2003) Transcription-coupled events associating with immunoglobulin switch region chromatin. *Science* 302:2137–2140
34. Strom L, Lundgren M, Severinson E (2003) Binding of Ikaros to germline Ig heavy chain gamma1 and epsilon promoters. *Mol Immunol* 39:771–782
35. Schaffer A, Kim EC, Wu X, Zan H, Testoni L, Salamon S, Cerutti A, Casali P (2003) Selective inhibition of class switching to IgG and IgE by recruitment of the HoxC4 and

- Oct-1 homeodomain proteins and Ku70/Ku86 to newly identified ATTT cis-elements. *J Biol Chem* 278:23141–23150
36. Kim EC, Edmonston CR, Wu X, Schaffer A, Casali P (2004) The HoxC4 homeodomain protein mediates activation of the immunoglobulin heavy chain 3' hs1,2 enhancer in human B cells. Relevance to class switch DNA recombination. *J Biol Chem* 279:42258–42269
 37. Laurencikiene J, Deveikaite V, Severinson E (2001) HS1,2 enhancer regulation of germline epsilon and gamma2b promoters in murine B lymphocytes: evidence for specific promoter-enhancer interactions. *J Immunol* 167:3257–3265
 38. Laurencikiene J, Tamosiunas V, Severinson E (2007) Regulation of epsilon germline transcription and switch region mutations by IgH locus 3' enhancers in transgenic mice. *Blood* 109:159–167
 39. Manis JP, van der Stoep N, Tian M, Ferrini R, Davidson L, Bottaro A, Alt FW (1998) Class switching in B cells lacking 3' immunoglobulin heavy chain enhancers. *J Exp Med* 188:1421–1431
 40. Hein K, Lorenz MG, Siebenkotten G, Petry K, Christine R, Radbruch A (1998) Processing of switch transcripts is required for targeting of antibody class switch recombination. *J Exp Med* 188:2369–2374
 41. Mao CS, Stavnezer J (2001) Differential regulation of mouse germline Ig gamma 1 and epsilon promoters by IL-4 and CD40. *J Immunol* 167:1522–1534
 42. Fear DJ, McCloskey N, O'Connor B, Felsenfeld G, Gould HJ (2004) Transcription of Ig germline genes in single human B cells and the role of cytokines in isotype determination. *J Immunol* 173:4529–4538
 43. Selsing E (2006) Ig class switching: targeting the recombinational mechanism. *Curr Opin Immunol* 18:249–254
 44. Zarrin AA, Alt FW, Chaudhuri J, Stokes N, Kaushal D, Du Pasquier L, Tian M (2004) An evolutionarily conserved target motif for immunoglobulin class-switch recombination. *Nat Immunol* 5:1275–1281
 45. Larson ED, Duquette ML, Cummings WJ, Streiff RJ, Maizels N (2005) MutSalptra binds to and promotes synapsis of transcriptionally activated immunoglobulin switch regions. *Curr Biol* 15:470–474
 46. Kaminski DA, Stavnezer J (2007) Stimuli that enhance IgA class switching increase histone 3 acetylation at S alpha, but poorly stimulate sequential switching from IgG2b. *Eur J Immunol* 37:240–251
 47. Wang L, Whang N, Wuerffel R, Kenter AL (2006) AID-dependent histone acetylation is detected in immunoglobulin S regions. *J Exp Med* 203:215–226
 48. Bradley SP, Kaminski DA, Peters AH, Jenuwein T, Stavnezer J (2006) The histone methyltransferase Suv39h1 increases class switch recombination specifically to IgA. *J Immunol* 177:1179–1188
 49. Zarrin AA, Tian M, Wang J, Borjeson T, Alt FW (2005) Influence of switch region length on immunoglobulin class switch recombination. *Proc Natl Acad Sci USA* 102:2466–2470
 50. Shinkura R, Ito S, Begum NA, Nagaoka H, Muramatsu M, Kinoshita K, Sakakibara Y, Hijikata H, Honjo T (2004) Separate domains of AID are required for somatic hypermutation and class-switch recombination. *Nat Immunol* 5:707–712
 51. Chaudhuri J, Khuong C, Alt FW (2004) Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. *Nature* 430:992–998
 52. Basu U, Chaudhuri J, Alpert C, Dutt S, Ranganath S, Li G, Schrum JP, Manis JP, Alt FW (2005) The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. *Nature* 438:508–511
 53. Muto A, Tashiro S, Nakajima O, Hoshino H, Takahashi S, Sakoda E, Ikebe D, Yamamoto M, Igarashi K (2004) The transcriptional programme of antibody class switching involves the repressor Bach2. *Nature* 429:566–571
 54. Borggrefe T, Keshavarzi S, Gross B, Wabl M, Jessberger R (2001) Impaired IgE response in SWAP-70-deficient mice. *Eur J Immunol* 31:2467–2475

55. Buckley RH, Wray BB, Belmaker EZ (1972) Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. *Pediatrics* 49:59–70
56. Davis SD, Schaller J, Wedgwood RJ (1966) Job's Syndrome. Recurrent, "cold", staphylococcal abscesses. *Lancet* 1:1013–1015
57. Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, Miller JA, O'Connell AC, Puck JM (1999) Hyper-IgE syndrome with recurrent infections – an autosomal dominant multisystem disorder. *N Engl J Med* 340:692–702
58. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schaffer AA, Puck JM, Grimbacher B (2007) STAT3 mutations in the hyper-IgE syndrome. *N Engl J Med* 357:1608–1619
59. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, Metin A, Karasuyama H (2007) Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. *Nature* 448:1058–1062
60. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh PA, Feinberg J, von Bernuth H, Samarina A, Janniere L, Fieschi C, Stephan JL, Boileau C, Lyonnet S, Jondeau G, Cormier-Daire V, Le Merrer M, Hoarau C, Lebranchu Y, Lortholary O, Chandesris MO, Tron F, Gambineri E, Bianchi L, Rodriguez-Gallego C, Zitnik SE, Vasconcelos J, Guedes M, Vitor AB, Marodi L, Chapel H, Reid B, Roifman C, Nadal D, Reichenbach J, Caragol I, Garty BZ, Dogu F, Camcioglu Y, Gulle S, Sanal O, Fischer A, Abel L, Stockinger B, Picard C, Casanova JL (2008) Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. *J Exp Med* 205:1543–1550
61. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. *Nature* 452:773–776
62. Schindler C, Plumlee C (2008) Interferons pen the JAK-STAT pathway. *Semin Cell Dev Biol* 122:401–408
63. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, Morse HC, 3rd, Liu C, Schwartzberg PL, Leonard WJ (2002) A critical role for IL-21 in regulating immunoglobulin production. *Science* 298:1630–1634
64. Kishida T, Hiromura Y, Shin-Ya M, Asada H, Kuriyama H, Sugai M, Shimizu A, Yokota Y, Hama T, Imanishi J, Hisa Y, Mazda O (2007) IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice. *J Immunol* 179:8554–8561
65. Haba S, Ovary Z, Nisonoff A (1985) Clearance of IgE from serum of normal and hybridoma-bearing mice. *J Immunol* 134:3291–3297
66. Hirano T, Hom C, Ovary Z (1983) Half-life of murine IgE antibodies in the mouse. *Int Arch Allergy Appl Immunol* 71:182–184
67. Hanashiro K, Tokeshi Y, Nakasone T, Sunagawa M, Nakamura M, Kosugi T (2001) Analysis of IgE turnover in non-sensitized and sensitized rats. *Mediators Inflamm* 10:217–221
68. Waldmann TA, Iio A, Ogawa M, McIntyre OR, Strober W (1976) The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. *J Immunol* 117:1139–1144
69. Brambell FW (1966) The transmission of immunity from mother to young and the catabolism of immunoglobulins. *Lancet* 2:1087–1093
70. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanesian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL (2003) The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. *J Immunol* 170:3528–3533
71. Lu W, Zhao Z, Zhao Y, Yu S, Zhao Y, Fan B, Kacsokovics I, Hammarstrom L, Li N (2007) Over-expression of the bovine FcRn in the mammary gland results in increased IgG levels in both milk and serum of transgenic mice. *Immunology* 19:311–318

72. Simister NE, Mostov KE (1989) An Fc receptor structurally related to MHC class I antigens. *Nature* 337:184–187
73. Ahouse JJ, Hagerman CL, Mittal P, Gilbert DJ, Copeland NG, Jenkins NA, Simister NE (1993) Mouse MHC class I-like Fc receptor encoded outside the MHC. *J Immunol* 151:6076–6088
74. Sutton BJ, Gould HJ (1993) The human IgE network. *Nature* 366:421–428
75. Yokota A, Kikutani H, Tanaka T, Sato R, Barsumian EL, Suemura M, Kishimoto T (1988) Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): tissue-specific and IL-4-specific regulation of gene expression. *Cell* 55:611–618
76. Delespesse G, Sarfati M, Wu CY, Fournier S, Letellier M (1992) The low-affinity receptor for IgE. *Immunol Rev* 125:77–97
77. Delespesse G, Suter U, Mossalayi D, Bettler B, Sarfati M, Hofstetter H, Kilcherr E, Debre P, Dalloul A (1991) Expression, structure, and function of the CD23 antigen. *Adv Immunol* 49:149–191
78. Maeda K, Burton GF, Padgett DA, Conrad DH, Huff TF, Masuda A, Szakal AK, Tew JG (1992) Murine follicular dendritic cells and low affinity Fc receptors for IgE (Fc epsilon RII). *J Immunol* 148:2340–2347
79. Rao M, Lee WT, Conrad DH (1987) Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE. *J Immunol* 138:1845–1851
80. Sukumar S, Conrad DH, Szakal AK, Tew JG (2006) Differential T cell-mediated regulation of CD23 (Fc epsilon RII) in B cells and follicular dendritic cells. *J Immunol* 176:4811–4817
81. Conrad DH (1990) Fc epsilon RII/CD23: the low affinity receptor for IgE. *Annu Rev Immunol* 8:623–645
82. Gould H, Sutton B, Edmeades R, Beavil A (1991) CD23/Fc epsilon RII: C-type lectin membrane protein with a split personality? *Monogr Allergy* 29:28–49
83. Chretien I, Helm BA, Marsh PJ, Padlan EA, Wijdenes J, Banchereau J (1988) A monoclonal anti-IgE antibody against an epitope (amino acids 367–376) in the CH3 domain inhibits IgE binding to the low affinity IgE receptor (CD23). *J Immunol* 141:3128–3134
84. Richards ML, Katz DH (1990) The binding of IgE to murine Fc epsilon RII is calcium-dependent but not inhibited by carbohydrate. *J Immunol* 144:2638–2646
85. Kilmon MA, Shelburne AE, Chan-Li Y, Holmes KL, Conrad DH (2004) CD23 trimers are preassociated on the cell surface even in the absence of its ligand, IgE. *J Immunol* 172:1065–1073
86. Dierks SE, Bartlett WC, Edmeades RL, Gould HJ, Rao M, Conrad DH (1993) The oligomeric nature of the murine Fc epsilon RII/CD23. Implications for function. *J Immunol* 150:2372–2382
87. Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S, Broadway N, Hartmann D, Saftig P, Umland S, Sehara-Fujisawa A, Black RA, Ludwig A, Becherer JD, Conrad DH, Blobel CP (2006) ADAM10 is a principal ‘shedase’ of the low-affinity immunoglobulin E receptor CD23. *Nat Immunol* 7:1293–1298
88. Lemieux GA, Blumenkron F, Yeung N, Zhou P, Williams J, Grammer AC, Petrovich R, Lipsky PE, Moss ML, Werb Z (2007) The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10. *J Biol Chem* 282:14836–14844
89. Bartlett WC, Kelly AE, Johnson CM, Conrad DH (1995) Analysis of murine soluble Fc epsilon RII sites of cleavage and requirements for dual-affinity interaction with IgE. *J Immunol* 154:4240–4246
90. Stief A, Texido G, Sansig G, Eibel H, Le Gros G, van der Putten H (1994) Mice deficient in CD23 reveal its modulatory role in IgE production but no role in T and B cell development. *J Immunol* 152:3378–3390
91. Getahun A, Hjelm F, Heyman B (2005) IgE enhances antibody and T cell responses in vivo via CD23+ B cells. *J Immunol* 175:1473–1482
92. Texido G, Eibel H, Le Gros G, van der Putten H (1994) Transgene CD23 expression on lymphoid cells modulates IgE and IgG1 responses. *J Immunol* 153:3028–3042

93. Payet M, Conrad DH (1999) IgE regulation in CD23 knockout and transgenic mice. *Allergy* 54:1125–1129
94. Cho SW, Kilmon MA, Studer EJ, van der Putten H, Conrad DH (1997) B cell activation and Ig, especially IgE, production is inhibited by high CD23 levels in vivo and in vitro. *Cell Immunol* 180:36–46
95. Carlsson F, Hjelm F, Conrad DH, Heyman B (2007) IgE enhances specific antibody and T-cell responses in mice overexpressing CD23. *Scand J Immunol* 66:261–270
96. Lewis G, Rapsomaniki E, Bouriez T, Crockford T, Ferry H, Rigby R, Vyse T, Lambe T, Cornell R (2004) Hyper IgE in New Zealand black mice due to a dominant-negative CD23 mutation. *Immunogenetics* 56:564–571
97. Flores-Romo L, Shields J, Humbert Y, Graber P, Aubry JP, Gauchat JF, Ayala G, Allet B, Chavez M, Bazin H (1993) Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. *Science* 261:1038–1041
98. Kilmon MA, Ghirlando R, Strub MP, Beavil RL, Gould HJ, Conrad DH (2001) Regulation of IgE production requires oligomerization of CD23. *J Immunol* 167:3139–3145
99. Nakamura T, Kloetzer WS, Brams P, Hariharan K, Chamat S, Cao X, LaBarre MJ, Chinn PC, Morena RA, Shestowsky WS, Li YP, Chen A, Reff ME (2000) In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain. *Int J Immunopharmacol* 22:131–141
100. Sherr E, Macy E, Kimata H, Gilly M, Saxon A (1989) Binding the low affinity Fc epsilon R on B cells suppresses ongoing human IgE synthesis. *J Immunol* 142:481–489
101. Munoz O, Brignone C, Grenier-Brossette N, Bonnefoy JY, Cousin JL (1998) Binding of anti-CD23 monoclonal antibody to the leucine zipper motif of Fc epsilon RII/CD23 on B cell membrane promotes its proteolytic cleavage. Evidence for an effect on the oligomer/monomer equilibrium. *J Biol Chem* 273:31795–31800
102. Wakai M, Pasley P, Sthoeger ZM, Posnett DN, Brooks R, Hashimoto S, Chiorazzi N (1993) Anti-CD23 monoclonal antibodies: comparisons of epitope specificities and modulating capacities for IgE binding and production. *Hybridoma* 12:25–43
103. Ford JW, Kilmon MA, Haas KM, Shelburne AE, Chan-Li Y, Conrad DH (2006) In vivo murine CD23 destabilization enhances CD23 shedding and IgE synthesis. *Cell Immunol* 243:107–117
104. Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY (1992) CD21 is a ligand for CD23 and regulates IgE production. *Nature* 358:505–507
105. Christie G, Barton A, Bolognese B, Buckle DR, Cook RM, Hansbury MJ, Harper GP, Marshall LA, McCord ME, Moulder K, Murdock PR, Seal SM, Spackman VM, Weston BJ, Mayer RJ (1997) IgE secretion is attenuated by an inhibitor of proteolytic processing of CD23 (Fc epsilon RII). *Eur J Immunol* 27:3228–3235
106. McCloskey N, Hunt J, Beavil RL, Jutton MR, Grundy GJ, Girardi E, Fabiane SM, Fear DJ, Conrad DH, Sutton BJ, Gould HJ (2007) Soluble CD23 Monomers Inhibit and Oligomers Stimulate IGE Synthesis in Human B Cells. *J Biol Chem* 282:24083–24091
107. Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, Hannan JP, Sutton BJ, Gould HJ, McDonnell JM (2005) The structure of human CD23 and its interactions with IgE and CD21. *J Exp Med* 202:751–760
108. Gauld SB, Benschop RJ, Merrell KT, Cambier JC (2005) Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. *Nat Immunol* 6:1160–1167
109. McHeyzer-Williams LJ, Malherbe LP, McHeyzer-Williams MG (2006) Checkpoints in memory B-cell evolution. *Immunol Rev* 211:255–268
110. Grupp SA, Campbell K, Mitchell RN, Cambier JC, Abbas AK (1993) Signaling-defective mutants of the B lymphocyte antigen receptor fail to associate with Ig-alpha and Ig-beta/gamma. *J Biol Chem* 268:25776–25779
111. Shaw AC, Mitchell RN, Weaver YK, Campos-Torres J, Abbas AK, Leder P (1990) Mutations of immunoglobulin transmembrane and cytoplasmic domains: effects on intracellular signaling and antigen presentation. *Cell* 63:381–392

112. Batista FD, Efremov DG, Burrone OR (1995) Characterization and expression of alternatively spliced IgE heavy chain transcripts produced by peripheral blood lymphocytes. *J Immunol* 154:209–218
113. Peng C, Davis FM, Sun LK, Liou RS, Kim YW, Chang TW (1992) A new isoform of human membrane-bound IgE. *J Immunol* 148:129–136
114. Zhang K, Saxon A, Max EE (1992) Two unusual forms of human immunoglobulin E encoded by alternative RNA splicing of epsilon heavy chain membrane exons. *J Exp Med* 176:233–243
115. Poggianella M, Bestagno M, Burrone OR (2006) The extracellular membrane-proximal domain of human membrane IgE controls apoptotic signaling of the B cell receptor in the mature B cell line A20. *J Immunol* 177:3597–3605
116. Batista FD, Anand S, Presani G, Efremov DG, Burrone OR (1996) The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors. *J Exp Med* 184:2197–2205
117. Venkataraman AR, Williams GT, Dariavach P, Neuberger MS (1991) The B-cell antigen receptor of the five immunoglobulin classes. *Nature* 352:777–781
118. Lam KP, Kuhn R, Rajewsky K (1997) In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. *Cell* 90:1073–1083
119. Patel KJ, Neuberger MS (1993) Antigen presentation by the B cell antigen receptor is driven by the alpha/beta sheath and occurs independently of its cytoplasmic tyrosines. *Cell* 74:939–946
120. Kaisho T, Schwenk F, Rajewsky K (1997) The roles of gamma 1 heavy chain membrane expression and cytoplasmic tail in IgG1 responses. *Science* 276:412–415
121. Sato M, Adachi T, Tsubata T (2007) Augmentation of signaling through BCR containing IgE but not that containing IgA due to lack of CD22-mediated signal regulation. *J Immunol* 178:2901–2907
122. Wakabayashi C, Adachi T, Wienands J, Tsubata T (2002) A distinct signaling pathway used by the IgG-containing B cell antigen receptor. *Science* 298:2392–2395
123. Ravetch JV, Lanier LL (2000) Immune inhibitory receptors. *Science* 290:84–89
124. Oberndorfer I, Schmid D, Geisberger R, Achatz-Straussberger G, Cramer R, Lamers M, Achatz G (2006) HS1-associated protein X-1 interacts with membrane-bound IgE: impact on receptor-mediated internalization. *J Immunol* 177:1139–1145
125. Erazo A, Kutchukhidze N, Leung M, Christ AP, Urban JF, Jr., Curotto de Lafaille MA, Lafaille JJ (2007) Unique maturation program of the IgE response in vivo. *Immunity* 26:191–203
126. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K (2003) Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. *Immunity* 19:607–620
127. Kelly KA, Butch AW (2007) Antigen-specific immunoglobulin E+ B cells are preferentially localized within germinal centres. *Immunology* 120:345–353
128. Auci DL, Chice SM, Heusser C, Athanassiades TJ, Durkin HG (1992) Origin and fate of IgE-bearing lymphocytes. II. Gut-associated lymphoid tissue as sites of first appearance of IgE-bearing B lymphocytes and hapten-specific IgE antibody-forming cells in mice immunized with benzylpenicilloyl-keyhole limpet hemocyanin by various routes: relation to asialo GM1 ganglioside+ cells and IgE/CD23 immune complexes. *J Immunol* 149:2241–2248
129. Wang CH, Richards EM, Block RD, Lezcano EM, Gutierrez R (1998) Early induction and augmentation of parasitic antigen-specific antibody-producing B lymphocytes in the non-Peyer's patch region of the small intestine. *Front Biosci* 3:A58–65
130. Galli G, Guise J, Tucker PW, Nevins JR (1988) Poly(A) site choice rather than splice site choice governs the regulated production of IgM heavy-chain RNAs. *Proc Natl Acad Sci USA* 85:2439–2443
131. Gerster T, Picard D, Schaffner W (1986) During B-cell differentiation enhancer activity and transcription rate of immunoglobulin heavy chain genes are high before mRNA accumulation. *Cell* 45:45–52

132. Phillips C, Jung S, Gunderson SI (2001) Regulation of nuclear poly(A) addition controls the expression of immunoglobulin M secretory mRNA. *EMBO J* 20:6443–6452
133. Christofori G, Keller W (1988) 3' cleavage and polyadenylation of mRNA precursors in vitro requires a poly(A) polymerase, a cleavage factor, and a snRNP. *Cell* 54:875–889
134. Gilmartin GM, Nevins JR (1989) An ordered pathway of assembly of components required for polyadenylation site recognition and processing. *Genes Dev* 3:2180–2190
135. Takagaki Y, Ryner LC, Manley JL (1989) Four factors are required for 3'-end cleavage of pre-mRNAs. *Genes Dev* 3:1711–1724
136. Takagaki Y, Manley JL, MacDonald CC, Wilusz J, Shenk T (1990) A multisubunit factor, CstF, is required for polyadenylation of mammalian pre-mRNAs. *Genes Dev* 4:2112–2120
137. Murthy KG, Manley JL (1995) The 160-kD subunit of human cleavage-polyadenylation specificity factor coordinates pre-mRNA 3'-end formation. *Genes Dev* 9:2672–2683
138. Murthy KG, Manley JL (1992) Characterization of the multisubunit cleavage-polyadenylation specificity factor from calf thymus. *J Biol Chem* 267:14804–14811
139. Keller W, Bienroth S, Lang KM, Christofori G (1991) Cleavage and polyadenylation factor CPF specifically interacts with the pre-mRNA 3' processing signal AAUAAA. *Embo J* 10:4241–4249
140. Beyer K, Dandekar T, Keller W (1997) RNA ligands selected by cleavage stimulation factor contain distinct sequence motifs that function as downstream elements in 3'-end processing of pre-mRNA. *J Biol Chem* 272:26769–26779
141. Takagaki Y, Manley JL (1997) RNA recognition by the human polyadenylation factor CstF. *Mol Cell Biol* 17:3907–3914
142. MacDonald CC, Wilusz J, Shenk T (1994) The 64-kilodalton subunit of the CstF polyadenylation factor binds to pre-mRNAs downstream of the cleavage site and influences cleavage site location. *Mol Cell Biol* 14:6647–6654
143. Wahle E, Lustig A, Jeno P, Maurer P (1993) Mammalian poly(A)-binding protein II. Physical properties and binding to polynucleotides. *J Biol Chem* 268:2937–2945
144. Wahle E, Keller W (1996) The biochemistry of polyadenylation. *Trends Biochem Sci* 21:247–250
145. Raabe T, Bolland FJ, Manley JL (1991) Primary structure and expression of bovine poly(A) polymerase. *Nature* 353:229–234
146. Moreira A, Takagaki Y, Brackenridge S, Wollerton M, Manley JL, Proudfoot NJ (1998) The upstream sequence element of the C2 complement poly(A) signal activates mRNA 3' end formation by two distinct mechanisms. *Genes Dev* 12:2522–2534
147. Takagaki Y, Seipelt RL, Peterson ML, Manley JL (1996) The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. *Cell* 87:941–952
148. Galli G, Guise JW, McDevitt MA, Tucker PW, Nevins JR (1987) Relative position and strengths of poly(A) sites as well as transcription termination are critical to membrane versus secreted mu-chain expression during B-cell development. *Genes Dev* 1:471–481
149. Guise JW, Lim PL, Yuan D, Tucker PW (1988) Alternative expression of secreted and membrane forms of immunoglobulin mu-chain is regulated by transcriptional termination in stable plasmacytoma transfectants. *J Immunol* 140:3988–3994
150. Yan DH, Weiss EA, Nevins JR (1995) Identification of an activity in B-cell extracts that selectively impairs the formation of an immunoglobulin mu s poly(A) site processing complex. *Mol Cell Biol* 15:1901–1906
151. Flaspohler JA, Milcarek C (1990) Myelomas and lymphomas expressing the Ig gamma 2a H chain gene have similar transcription termination regions. *J Immunol* 144:2802–2810
152. Flaspohler JA, Boczkowski D, Hall BL, Milcarek C (1995) The 3'-untranslated region of membrane exon 2 from the gamma 2a immunoglobulin gene contributes to efficient transcription termination. *J Biol Chem* 270:11903–11911
153. Lebman DA, Park MJ, Fatica R, Zhang Z (1992) Regulation of usage of membrane and secreted 3' termini of alpha mRNA differs from mu mRNA. *J Immunol* 148:3282–3289

154. Edwalds-Gilbert G, Veraldi KL, Milcarek C (1997) Alternative poly(A) site selection in complex transcription units: means to an end? *Nucleic Acids Res* 25:2547–2561
155. Coyle JH, Lebman DA (2000) Correct immunoglobulin alpha mRNA processing depends on specific sequence in the C alpha 3-alpha M intron. *J Immunol* 164:3659–3665
156. Anand S, Batista FD, Tkach T, Efremov DG, Burrone OR (1997) Multiple transcripts of the murine immunoglobulin epsilon membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites. *Mol Immunol* 34:175–183
157. Batista FD, Efremov DG, Burrone OR (1996) Characterization of a second secreted IgE isoform and identification of an asymmetric pathway of IgE assembly. *Proc Natl Acad Sci USA* 93:3399–3404
158. Manz RA, Hauser AE, Hiepe F, Radbruch A (2005) Maintenance of serum antibody levels. *Annu Rev Immunol* 23:367–386
159. Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A (1998) Survival of long-lived plasma cells is independent of antigen. *Int Immunol* 10:1703–1711
160. Manz RA, Thiel A, Radbruch A (1997) Lifetime of plasma cells in the bone marrow. *Nature* 388:133–134
161. Holt PG, Sedgwick JD, O'Leary C, Krska K, Leivers S (1984) Long-lived IgE- and IgG-secreting cells in rodents manifesting persistent antibody responses. *Cell Immunol* 89:281–289
162. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, Radbruch A, Hiepe F, Manz RA (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. *J Exp Med* 199:1577–1584
163. Hauser AE, Debes GF, Arce S, Cassese G, Hamann A, Radbruch A, Manz RA (2002) Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. *J Immunol* 169:1277–1282
164. Hauser AE, Muehlinghaus G, Manz RA, Cassese G, Arce S, Debes GF, Hamann A, Berek C, Lindenau S, Doerner T, Hiepe F, Odendahl M, Riemekasten G, Krenn V, Radbruch A (2003) Long-lived plasma cells in immunity and inflammation. *Ann N Y Acad Sci* 987:266–269
165. Hargreaves DC, Hyman PL, Lu TT, Ngo VN, Bidgol A, Suzuki G, Zou YR, Littman DR, Cyster JG (2001) A coordinated change in chemokine responsiveness guides plasma cell movements. *J Exp Med* 194:45–56
166. Muehlinghaus G, Cigliano L, Huehn S, Peddinghaus A, Leyendeckers H, Hauser AE, Hiepe F, Radbruch A, Arce S, Manz RA (2005) Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. *Blood* 105:3965–3971
167. Achatz-Straussberger G, Zaborsky N, Konigsberger S, Luger EO, Lamers M, Crameri R, Achatz G (2008) Migration of antibody secreting cells towards CXCL12 depends on the isotype that forms the BCR. *Eur J Immunol* 38:3167–3177
168. Leffell MS, Donnenberg AD, Rose NR. *Handbook of Human Immunology*. 1 ed. Boca Raton FL: CRC Press, 1997
169. Peppard JV, Orlans E (1980) The biological half-lives of four rat immunoglobulin isotypes. *Immunology* 40:683–686
170. Medesan C, Cianga P, Mummert M, Stanescu D, Ghetie V, Ward ES (1998) Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site. *Eur J Immunol* 28:2092–2100



<http://www.springer.com/978-1-60761-450-0>

Cancer and IgE

Introducing the Concept of AllergoOncology

Penichet, M.L.; Jensen-Jarolim, E. (Eds.)

2010, IX, 287 p., Hardcover

ISBN: 978-1-60761-450-0

A product of Humana Press